The Optimal Treatment of Severe Hypertension in Pregnancy: Update of the Role of Nicardipine

ISSN: 1873-4316 (Online)
ISSN: 1389-2010 (Print)

Volume 18, 15 Issues, 2017

Download PDF Flyer

Current Pharmaceutical Biotechnology

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 152nd of 255 in Pharmacology & Pharmacy
  • 213th of 290 in Biochemistry & Molecular Biology

Submit Abstracts Online Submit Manuscripts Online

Zeno Foldes-Papp
Urban Clinical Center Soltau
University teaching hospital of Hamburg

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 1.802
5 - Year: 2.327

The Optimal Treatment of Severe Hypertension in Pregnancy: Update of the Role of Nicardipine

Current Pharmaceutical Biotechnology, 15(1): 64-69.

Author(s): Linda S. Nooij, Sanne Visser, Tess Meuleman, Paul Vos, Robin Roelofs and Christianne JM de Groot.

Affiliation: Department of Obstetrics and Gynecology, VUMC, De Boelelaan 1117, 1081 HZ Amsterdam, The Netherlands.


Objective: Hypertensive disorders in pregnancy remain a major cause of maternal morbidity and mortality. Blood pressure control is essential for maternal and neonatal outcome. Therefore, we analyzed the potency and side effects of two treatment options (nicardipine compared to labetalol) in order to gain insight in improved treatment of severe hypertension during pregnancy and to evaluate the feasibility of a randomised controlled trial. Study design: A nested case control study in an inner city teaching hospital alongside a meta-analysis. Data from women who received nicardipine were compared with patients who received labetalol during pregnancy. Primary outcome measure was successful control of severe hypertension. Secondary outcome measures were maternal and neonatal side effects. These results were included in a meta-analysis. Results: Only one previous study described nicardipine in comparison to labetalol during pregnancy. The combined results indicate a similar success-rate of treatment with nicardipine compared to labetalol during pregnancy. Women treated with nicardipine had more often tachycardia, headache and nausea compared to women treated with labetalol. Hypotension resulting in fetal distress was found more often in the labetalol group. Conclusion: Nicardipine is a potent drug to control hypertension during pregnancy with side effects including maternal headaches, nausea and tachycardia. Labetalol had more neonatal side effects including hypotension compared with nicardipine. These results support the justification and prove that it is safe to perform a randomized controlled trial comparing nicardipine to labetalol in the treatment of severe hypertension in pregnancy.


Ketanserin, labetalol, nicardipine, pre-eclampsia, pregnancy induced hypertension, treatment.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 15
Issue Number: 1
First Page: 64
Last Page: 69
Page Count: 6
DOI: 10.2174/1389201015666140330194722
Pharmaceutical Microbiology 2017

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science